Watch Ticker

BeyondSpring Inc. Ordinary Shares

Go to BeyondSpring Inc. Ordinary Shares Website

$2.58

(%)
Live
Previous Close

$2.58

Day Range

$ - $

Previous Day Range

$ - $

Market Cap

$100.7 million USD

Day Vol.

Previous Day Vol.

Currency

USD

Primary Exchange

Nasdaq

BeyondSpring Inc is engaged in clinical-stage biopharmaceutical activities focused on the development of cancer therapies. It is also focused on including immuno-oncology agents. It has two reportable segments Plinabulin pipeline and the TPD platform...

Community
  • 0 posts discussing
0

Watchers

0

Visitors

Recent News

FLORHAM PARK, N.J., May 03, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced it will host a Research and Development (R&D) Day to discuss the current unmet medical needs and the potential of Plinabulin as a novel immunochemotherapeutic in drug combinations and updates for SEED Therapeutics on Wednesday, May 15th, 2024 at 10:00 a.m. ET.

Related tickers: BYSI.

Read Full Article

FLORHAM PARK, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing innovative cancer therapies, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the U.S. Securities and Exchange Commission (“SEC”) on April 29, 2024. The annual report on Form 20-F, which contains the Company’s audited consolidated financial statements, can be accessed on the SEC’s website at www.sec.gov and on the Company’s website at www.beyondspringpharma.com under “Financials & Filings” in the Investors section.

Related tickers: BYSI.

Read Full Article
Trending Tickers
AMBO

XASE

$1.35
(%)
LASE

XNAS

$2.62
(%)
SMFL

XNAS

$2.70
(%)
BFRG

XNAS

$2.99
(%)
MLGO

XNAS

$0.00
(%)